Development and optimization of cosolvent-based blended Sertraline orodispersible films - A step to personalized medicine
DOI:
https://doi.org/10.1590/s2175-97902022e20584Keywords:
Orodispersible films, Personalized medicine, Sertraline, Modified in-vitro disintegration time, Pore-forming agentAbstract
Personalized medicine is gaining importance in pharmacotherapeutics as it allows tailoring the drug treatment to achieve the best patient response. Orodispersible film (ODF) is easy to formulate in hospitals, produces dose flexibility to suit an individual needs, particularly for patients suffer from swallowing issues or prohibited to take fluids. Sertraline Hydrochloride (SRT) was solubilized in several cosolvents, then different SRT ODFs based on five hydrophilic polymers namely; polyvinyl alcohol (PVA), hydroxylethyl cellulose (HEC), hydroxypropyl methylcellulose E5 LV (HPMC E5 LV), sodium alginate (NaAlg) and gelatin at two concentrations (2% and 4%) were developed and characterized. The outcomes were exposed to response surface analysis to obtain the desirability results to obtain the optimized formulation. Blended ODFs were developed from 4% PVA and 2% HEC in different blends and then potassium chloride (KCl) as a pore-forming agent was added to the best formulation to investigate its dissolution enhancement effect. F14 containing 4% PVA: 2% HEC 2:1 with 5% KCl showed best physicochemical properties of suitable pH (5.6), disintegration time (6 sec), good folding endurance which released 91 % SRT after 15 min. SRT ODF is an encouraging delivery system in the course of personalized medicine for the management of depression.
Downloads
References
Abouhussein D, El Nabarawi MA, Shalaby SH, Abd El-Bary A. Cetylpyridinium chloride chitosan blended mucoadhesive buccal films for treatment of pediatric oral diseases. J Drug Delivery Sci Technol. 2020;57:1-9.
Abouhussein D, Sabry P, Moghawry MH. Recent insight into critical concerns in international quality regulations governing the pharmaceutical industry: A Review. Int J Pharm Res. 2019a;11:708-718.
Abouhussein DM, Mahmoud DB, Mohammad FE. Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases. J Liposome Res. 2019b;29(4):399-412.
Abouhussein DM, El Nabarawi MA, Shalaby SH, El-Bary AA. Sertraline-cyclodextrin complex orodispersible sublingual tablet: optimization, stability, and pharmacokinetics. J Pharm Innovation. 2021;16:53-66.
Abouhussein DM, Khattab A, Bayoumi NA, Mahmoud AF, Sakr TM. Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: Optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J Drug Delivery Sci Technol . 2018;43:129-140.
Aframian D, Davidowitz T, Benoliel R. The distribution of oral mucosal pH values in healthy saliva secretors. Oral diseases. 2006;12(4):420-423.
Al-Nimry SS, Jaber MA. Preparation and optimization of sertraline hydrochloride tablets with improved dissolution through crystal modification. AAPS PharmSciTech. 2017;18(4):1190-1202.
Amin K, Dannenfelser RM, Zielinski J, Wang B. Lyophilization of polyethylene glycol mixtures. J Pharm Sci. 2004;93(9):2244-2249.
Borges AF, Silva C, Coelho JF, Simões S. Oral films: current status and future perspectives: I-galenical development and quality attributes. J Control Release. 2015;206:1-19.
Bucknall CB, Paul DR. Polymer Blends: Formulation and Performance. Wiley, New York. 2000.
Chisca S, Sava I, Bruma M. Porous polyimide films obtained by using lithium chloride as pore-forming agent. Polym Int. 2013;62(11):1634-1643.
El-Bary AA, Shalaby S, El Nabarawi M, Abouhussein D. Formulation and evaluation of Sertraline HCl sublingual oral disintegrating tablets using factorial design. Inventi Impact: Pharm Tech. 2015;1:56-63.
FDA. Guidance for industry orally disintegrating tablets. Silver Spring, MD: Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER) at FDA. 2008.
Khattab A, Abouhussein DM. Development of injectable tenoxicam in situ forming microparticles based on sesame oil and poly-DL-lactide: Characterization, efficacy and acute toxicity. J Drug Delivery Sci Technol . 2019;51(2):682-694.
Lakshmi P, Sreekanth J, Sridharan A. Formulation development of fast releasing oral thin films of levocetrizine dihydrochloride with Eudragit® Epo and optimization through Taguchi orthogonal experimental design. Asian J Pharm. 2014;5(2):84-92.
Li N, Wang N, Wu T, Qiu C, Wang X, Jiang S, et al. Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug. Drug Dev Ind Pharm. 2018;44(12):1966-1974.
Marques MR, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolution Technol. 2011;18(3):15-28.
Nafee NA, Boraie MA, Ismail FA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharmaceutica. 2003;53(3):199-212.
Nair AB, Kumria R, Harsha S, Attimarad M, Al-Dhubiab BE, Alhaider IA. In vitro techniques to evaluate buccal films. J Control Release . 2013;166(1):10-21.
Orlu M, Ranmal SR, Sheng Y, Tuleu C, Seddon P. Acceptability of orodispersible films for delivery of medicines to infants and preschool children. Drug delivery. 2017;24(1):1243-1248.
Pechová V, Gajdziok J, Muselík J, Vetchý D. Development of orodispersible films containing benzydamine hydrochloride using a modified solvent casting method. AAPS PharmSciTech . 2018;19(6):2509-2518.
Preis M, Gronkowsky D, Grytzan D, Breitkreutz J. Comparative study on novel test systems to determine disintegration time of orodispersible films. J Pharm and Pharmacol. 2014;66(8):1102-1111.
Rodd C, Jean-Philippe S, Vanstone C, Weiler H. Comparison of 2 vitamin D supplementation modalities in newborns: adherence and preference. App Phys Nut Metab. 2011;36(3):414-418.
Sanghai P, Nandgude T, Poddar S. Formulation of bilayer benzydamine HCl patch targeted for gingivitis. J Drug Delivery. 2016;2016:1-9.
Scarpa M, Paudel A, Kloprogge F, Hsiao WK, Bresciani M, Gaisford S. Key acceptability attributes of orodispersible films. Eur J Pharm Biopharm. 2018;125:131-140.
Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. EurJ Pharm Sci . 2015;75:2-9.
Sudhakar Y, Kuotsu K, Bandyopadhyay A. Buccal bioadhesive drug delivery-a promising option for orally less efficient drugs. J Control Release . 2006;114(1):15-40.
Tang YF, Du YM, Hu XW, Shi XW. Kennedy JF. Rheological characterisation of a novel thermosensitive chitosan/ poly (vinyl alcohol) blend hydrogel. Carbohydr Polym. 2007;67(4):491-499.
Visser JC, Wibier L, Mekhaeil M, Woerdenbag HJ, Taxis K. Orodispersible films as a personalized dosage form for nursing home residents, an exploratory study. Int J Clin Pharm. 2020;42(7):1-9.
Visser JC, Woerdenbag HJ, Crediet S, Gerrits E, Lesschen MA, Hinrichs WL, et al. Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations. Int J Pharm. 2015;478(1):155-163.
Visser JC, Woerdenbag HJ, Hanff LM, Frijlink HW. Personalized medicine in pediatrics: the clinical potential of orodispersible films. AAPS PharmSciTech . 2017;18(2):267-272.
Woertz C, Kleinebudde P. Development of orodispersible polymer films containing poorly water soluble active pharmaceutical ingredients with focus on different drug loadings and storage stability. Int J Pharm . 2015;493(1-2):134-145.
Yasmeen BR, Firoz S, Mouli YC, Vikram A, Mahitha B, Aruna U. Preparation and evaluation of oral fast dissolving films of citalopram hydrobromide. Int J Biopharm. 2012;3:103-106.
Yeh MK, Chang LC, Chiou AHJ. Improving tenoxicam solubility and bioavailability by cosolvent system. AAPS PharmSciTech . 2009;10(1):166-171.
Yuan L, Yu J, Zhang S. Effect of pore-forming agent on porous reaction-bonded silicon nitride ceramics, IOP Conference Series: Mat Sci Engineer. IOP Publishing. 2011;p. 222011.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
